The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Involvement of Advanced Glycation End Products in the Pathogenesis of Diabetic Retinopathy
Open accessAbstract
Diabetic retinopathy (DR) is a common and devastating microvascular complication of diabetes and a major cause of acquired blindness in young adults. Advanced glycation end products (AGEs) accumulated under hyperglycemic conditions are thought to play an important role in the pathogenesis of DR. AGEs can exert their deleterious effects by acting directly to induce aberrant crosslinking of extracellular matrix proteins, to increase vascular stiffness, altering vascular structure and function. Moreover, AGEs binding to the receptor for AGEs (RAGE) evokes intensive intracellular signaling cascades that leading to endothelial dysfunction, elaboration of key proinflammatory cytokines and proangiogenic factors, mediating pericyte apoptosis, vascular inflammation and angiogenesis, as well as breakdown of the inner blood-retinal barrier (BRB), the end result of all these events is damage to the neural and vascular components of the retina. Elucidation of AGE-induced mechanisms will help in the understanding of the complex cellular and molecular pathogenesis associated with DR. Novel anti-AGEs agents or AGE crosslink “breakers” are being investigated, it is hoped that in next few years, some of these promising therapies will be successfully applied in clinical context, aiming to reduce the major economical and medical burden caused by DR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In blood vessels, accumulated AGEs also interact with mononuclear, endothelial, and smooth muscle cells, resulting in cellular dysfunction, tissue damage, and atherosclerosis development55–57,59.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [56]
In the citing paper
“AGEs play important roles in diabetic microvascular complications by cross-linking with extracellular matrix proteins, thereby altering vascular elasticity, structure, and function56.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [56]
In the citing paper
“The accumulation and exposure to AGEs exacerbate oxidative stress and inflammation and initiate the oxidation of low-density lipoproteins (LDLs), which are harmful to cardiovascular function.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [56]
In the citing paper
“In addition, the AGE-RAGE interaction further instigates pericyte apoptosis, vascular inflammation and permeability, and blood-tissue barrier breakdown56.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [56]
In the citing paper
“Endogenous and exogenous AGEs provoke the initiation and progression of NAFLD.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [56]
In the citing paper
“The aggregation of AGEs decreases the levels of the most important cellular antioxidant peptides, glutathione (GSH), SIRT1, and tissue inhibitor of metalloproteinase 3 (TIMP3), accompanied by increased oxidative stress and inflammation, promoting inflammatory liver injury and fibrosis in experimental animal models and NAFLD patients55–57,124–126.”
From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [56]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Lang, G. E., Vaiser, A., Snyder, W. B., & Lynn, J. R. (2007) · Developments in ophthalmology · doi:10.1159/isbn.978-3-318-01439-6 · Cited by 5,607
Endothelial/Pericyte Interactions
Armulik, A., Abramsson, A., & Betsholtz, C. (2005) · Circulation Research · doi:10.1161/01.res.0000182903.16652.d7 · Cited by 2,048
A central role for inflammation in the pathogenesis of diabetic retinopathy
Joussen, A. M., Poulaki, V., Le, M. L., Koizumi, K., Esser, C., Janicki, H., Schraermeyer, U., Kociok, N., Fauser, S., Kirchhof, B., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-1476fje · Cited by 1,178
Koschinsky, T., He, C.-J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C., Heitmann, K., & Vlassara, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6474 · Cited by 792
Klaassen, I., Noorden, C. J. F. V., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 738
Epidemiology of diabetic retinopathy and macular oedema: A systematic review
Williams, R., Airey, M., Baxter, H., Forrester, J., Kennedy-Martin, T., & Girach, A. (2004) · Eye · doi:10.1038/sj.eye.6701476 · Cited by 472
McCance, D. R., Dyer, D. G., Dunn, J. A., Bailie, K., Thorpe, S. R., Baynes, J., & Lyons, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116482 · Cited by 444
Romeo, G. R., Liu, W.-H., Asnaghi, V., Kern, T. S., & Lorenzi, M. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2241 · Cited by 413
Basta, G. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.025 · Cited by 361
Cited by
Sorted by citations
Twarda‐Clapa, A., Olczak, A., Białkowska, A. M., & Koziołkiewicz, M. (2022) · Cells · doi:10.3390/cells11081312 · Cited by 829
Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy
Lin, K., Hsih, W., Lin, Y., Wen, C., & Chang, T. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13480 · Cited by 446
Rungratanawanich, W., Qu, Y., Wang, X., Essa, M. M., & Song, B.-J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00561-7 · Cited by 411
Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies
Rodríguez, M. L., Pérez, S., Mena, S., Desco, C., & Ortega, Á. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4940825 · Cited by 234
Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy
Rudraraju, M., Narayanan, S. P., & Somanath, P. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105115 · Cited by 217
Metadata
- Authors
- Xu, J., Chen, L.-J., Yu, J., Wang, H.-J., Zhang, F., Liu, Q., & Wu, J.
- Affiliations
- Nanfang Hospital (CN)
- Venue
- Cellular Physiology and Biochemistry
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 48
- Issue
- 2
- Pages
- 705-717
- ISSN
- 1015-8987 (ISSN-L)
- 1421-9778
- OpenAlex
- W2883415922
- Cited by
- 204
- References
- 73
- Citations by year
- 2026: 13 · 2025: 28 · 2024: 21 · 2023: 28 · 2022: 35 · 2021: 33 · 2020: 31 · 2019: 14 · 2018: 1
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cellular Physiology and Biochemistry (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Science and Technology Planning Project of Guangdong Province
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
- Keywords
- diabetic retinopathy, advanced glycation end products, receptor for advanced glycation end products, hyperglycemia, extracellular matrix cross-linking, vascular stiffness, endothelial dysfunction, pericyte apoptosis, angiogenesis, vascular inflammation, blood-retinal barrier breakdown, retinal microvascular complications
- MeSH terms
- Receptor for Advanced Glycation End Products, Blood-Retinal Barrier, Diabetic Retinopathy, Humans, Glycation End Products, Advanced, Reactive Oxygen Species, Vascular Endothelial Growth Factor A, Endoplasmic Reticulum Stress, Tight Junction Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
